ColoCare Study: Understanding Colorectal Cancer Outcomes
The ColoCare Study is an international research project looking at how colorectal cancer (cancer of the colon or rectum) affects patients over time. This study doesn't test new treatments; instead, it observes patients to understand factors that influence their recovery and overall health. Researchers are interested in how long patients live, if their cancer comes back, and their quality of life. You might be able to join if you are 18 to 89 years old and have been newly diagnosed with stage I-IV colorectal cancer. For those joining after September 1, 2021, the age range is generally 18-69, with some exceptions. The study aims to follow 5000 participants for up to 10 years to see how they do.
- Study design
- This is an observational study, meaning researchers will watch and collect information from 5000 participants with colorectal cancer. It is not testing a specific drug or intervention.
- What's involved
- You would be recruited at the time of your diagnosis and followed for up to 5 years with regular check-ins at 3, 6, 12, 24, 36, 48, and 60 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for disease-free and overall survival for up to 10 years, and for recurrence for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
ColoCare Study - Colorectal Cancer Cohort
At a glance
Conditions
Where it's being run
7 sites across 7 statesStudy leadership
- Cornelia M Ulrich, MS, PhD · PRINCIPAL_INVESTIGATOR · Huntsman Cancer Institute
- William Grady, MD, PhD · PRINCIPAL_INVESTIGATOR · Fred Hutchinson Cancer Center
- Christopher Li, MD · PRINCIPAL_INVESTIGATOR · Fred Hutchinson Cancer Center
- Doratha Byrd, PhD · PRINCIPAL_INVESTIGATOR · Lee H. Moffitt Cancer Center
- Jane Figueiredo, PhD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center
- David Shibata, MD · PRINCIPAL_INVESTIGATOR · University of Tennesee
- Adetunji T. Toriola, MD, PhD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
- Biljana Gigic, PhD · PRINCIPAL_INVESTIGATOR · Heidelberg University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Disease-free and overall survivalup to 10 years
- Recurrenceup to 5 years